Newsquawk Logo

Novo Nordisk (NOVOB DC) to cut Ozempic and Wegovy prices by up to 50% starting January 2027, according to WSJ; WeGovy and Ozempic will list for USD 675/month

Novo Nordisk's decision to cut prices on Ozempic and Wegovy by up to 50% signals a strategic move aimed at increasing market share and addressing competitive pressures from companies like Eli Lilly.

Newsquawk StaffPublished On the live feed at — 4 more headlines followed before this page went public
Newsquawk headlinesUTC

NRG Energy Inc. (NRG) Q4 2025 (USD): EPS 1.04 (exp. 1.02), Revenue -- (exp. 6.33bln)

JPM Treasury Client Survey (W/e 23rd Feb): All client survey shows least amount of short positions since December 15th; Active client shorts drop by four

Novo Nordisk (NOVOB DC) to cut Ozempic and Wegovy prices by up to 50% starting January 2027, according to WSJ; WeGovy and Ozempic will list for USD 675/month

Keurig Dr Pepper Inc. (KDP) Q4 2025 (USD): Adj. EPS 0.60 (exp. 0.59), Revenue 4.50bln (exp. 4.36bln)

Iranian oil loadings rise as regional risks intensify ahead of talks, via WSJ

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Try the platform free
Free. No signup, no card.
Context

This pricing shift, effective in January 2027, could enhance accessibility to these blockbuster drugs, potentially impacting revenue projections and shareholder sentiment as investors assess the long-term implications for the pharmaceutical sector.

Related headlines

The whole workspace, free to try.

Try it free
Newsquawk Logo

© 2026 Newsquawk. All rights reserved.